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Abstract 
The aim of this study is to analyze a group of patients with chronic lymphoproliferative disorders associated with B, 
C, D hepatitis viral infection. This group of chronic lymphoproliferative disordered patients with associated hepatitis viral 
infection has been diagnosed and monitored in the Hematology Department of the University Emergency Hospital of 
Bucharest, between December 2007 and January 2009. Our study is meant to observe the influence of the viral infection on 
clinical and biological evolution of the enrolled patients. 
The diagnosis of the chronic lymphoproliferative disorder was based on the bone marrow / lymph node biopsy and 
flow-cytometry analysis. The positive diagnosis for hepatitis viral infection was established by ELISA serological tests and 
viremia was performed by TaqMan method at INBI “Matei Bals” Bucharest. 
The analyzed group is made up of 41 patients, 25/41 (60,97%) females and 16/41 (39,02%) males, with ages: 20-50 
years old – 6/41 (14,63%), 51-70 years old – 23/41 (56,09%) and over 71 years old – 12/41 (29,26%) patients. The 
histological types of CLD: B-cell non-Hodgkin’s lymphoma – in 28/41 (68,29%) patients, T-cell non-Hodgkin’s lymphoma – 
2/41 (4,87%) patients, Hodgkin’s lymphoma – 2/41 (4,87%), chronic lymphocytic leukemia  - 7/41 (17,07%), Waldenström 
disease – 2/41 (4,87%) patients. Regarding the type of CLD, 19/41 (46,34%) of the patients have an aggressive type of CLD 
and 22/41 (53,65%) a non-aggressive type of CLD. The hepatitis viral infection distribution in our patients: 14/41 (34,14%) 
have HBV infection, 24/41 (58,53%) have HCV infection, double/triple association of viral infection was found in 3/41 (7,31%) 
patients. Within HBV infection subgroup 9/14 (64,28%) patients have an aggressive type of CLD and 5/14 (35,71%) patients 
have a non-aggressive type, whereas within the group with HCV infection we found a different distribution: 9/24 (37,5%) 
patients with aggressive type and 15/24 (62,5%) with non-aggressive type of CLD. The clinical parameters monitored were: B 
signs were present in 19/41 (43,34%) patients, the superficial or profound adenopathies –were found in 29/41 (70,73%) 
patients, hepatomegaly – in 38/41 (92,68%) patients, splenomegaly – in 21/41 (51,21%) patients,  extra-nodal involvements  in 
10/41 (24,39%) patients and most frequent in the non-aggressive type of CLD – 6/10 (60%) patients. The hematological and 
biochemical parameters were: the presence of anemia and thrombocytopenia - found in a small number of patients; 
lymphocytosis – positive in 33/41 (80,48%) patients, most with HCV infection and non-aggressive type of disease, the 
presence of autoimmune hemolytic anemia – in 4/41 (9,75%) patients, cryoglobulins – 8/41 (19,51%) patients, all with HCV 
infection; also the liver function was monitored. Antiviral therapy was administered to 12/41 (29,26%) patients – Lamivudine to  
8/41 (19,51%) patients and Ribavirine/Interferon to 4/41 (9,75%) patients. Chemotherapy was given in 32/41 (78%) patients. 
Monoclonal antibodies anti CD20 (Rituximab) therapy was associated in 6/41 (14,63%) patients.  
Conclusions. A high incidence in female sex of over 50 years old was noticed. A strong association between B-cell 
chronic lymphoproliferative disorders and hepatitis viral infection B, C, D was revealed, the most frequent being the C hepatitis 
virus, associated with the non-aggressive type of CLD, extra-nodal involvement, splenomegaly, lymphocytosis, cryoglobulins, 
cytolysis and colestasis. The clinical and biological disease history will be monitored during chemotherapy and antiviral 
treatment.   
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Background 
HBV infections and chronic 
lymphoproliferative disorders 
The hepatitis viral infections are frequent in 
patients with chronic lymphoproliferative disorders, being 
involved in their pathogeny and contributing to the 
morbidity and mortality of these patients. HBV acute 
infection could evolve to spontaneous recovery in 90% of 
the cases or could become a chronic infection, the risk 
decreasing with age (5-10% in adults). The risk is higher 
in immunosupressed patients. Due to the fact that HBV 
has a special hepatic tropism, it was revealed that there 
are small quantities of non-replicative HBV-DNA or viral 
antigens in mononuclear cells from peripheral blood such 
as monocytes, B-lymphocytes, CD4 and CD8 T-
lymphocytes, leading to the idea that the lymphocytes 
represent an extrahepatic viral reservoir. 
 
HCV infection and chronic 
lymphoproliferative disorders 
The HCV acute infection is asymptomatic in 75% 
of the cases, becoming chronic in 80% of the cases, 
much more frequent than HBV infection, and evolving to 
hepatic cirrhosis in a period of 5-30 years. HCV is a 
hepatotrop virus, but it is able to infect and replicate in 
hematopoietic cells, a lot of studies showing the presence 
of RNA-HCV within B, T-lymphocytes and monocytes in 
patients with HCV infection.  
Objectives 
We have performed a retrospective and 
prospective study of patients with CLD associating 
hepatitis viral infections diagnosed in the Hematology 
Department of SUUB starting with December 2007. The 
objectives included the positive diagnosis of chronic 
lymphoproliferative disorder, the statistic analysis of 
clinical and biological parameters, the correlations 
between these parameters and the identification of 
prognostic markers. 
The positive diagnosis was established 
according to the International Guidelines: 
1.  For chronic lymphocytic leukemia (CLL), 
after National Cancer Institute (NCI) (7) - lymphocytosis > 
5 x 109/L in peripheral blood and confirmation by flow-
cytometry of lymphocytes [1]. 
2.  For non-Hodgkin’s lymphoma (NHL) – by 
assessing the malignant lymphoid population with special 
immunophenotype, by immunohystochemistry or 
immunophenotyping, using modified REAL [2] and WHO 
classifications [3, 4].  
The inclusion criteria are: positive diagnosis of a 
B or T chronic lymphoproliferative disorder (established 
on leukocytosis with lymphocytosis, flow-cytometry on 
peripheral blood or bone marrow, bone marrow aspirate, 
bone marrow biopsy, lymph node biopsy, 
immunohystochemistry) and infection with hepatitis 
viruses (B, C, D). 
The exclusion criteria was the absence of 
hepatitis viruses infection. 
Material and methods 
We monitored clinical parameters, obtained from 
patients’ files, such as B signs (weight loss > 10% from 
body weight, fever, sweats), the presence of 
adenopathies, hepatomegaly, splenomegaly, the extra-
nodal and bone marrow involvement, the clinical signs of 
liver disease (jaundice, peritoneal liquid, collateral 
circulation). The biological parameters monitored were: 
-  anemia – Hb < 11 g/dl 
-  thrombocytopenia PLT < 150.000/mm³ 
-  lymphocytosis > 20% lymphocytes 
-  presence of autoimmune hemolytic anemia 
-  the value of serum LDH 
-  kidney tests (BUN, creatinine), uric acid 
-  liver tests (GOT, GPT, alkaline phosphatase, 
GGT), total bilirubine with fractions 
-  the presence of cryoglobulins 
-  coagulation changes 
The blood cell count was performed in the 
Hematology Laboratory of The Hematology Department of 
University Emergency Hospital of Bucharest, including the 
morphologic analysis of the blood smear. The biochemical 
tests were performed in the Laboratory of SUUB. 
Results 
The patients enrolled in this analysis were 
diagnosed and monitored in our department from 
December 2007 until January 2009. 
In the group, there were 41 patients with CLD 
and B/C/D hepatitis viral infection, among whom 25 
females (25/41=60,97%) and 16 males (16/41=39,02%). 
The median age of the group was of 64 (min 30, max 85) 
years old, and the patients’ distribution according to the 
age was: 20-50 years old – 6/41 (14,63%) patients, 51-70 
years old – 23/41 (56,09%) patients and over 70 years old 
– 12/41 (29,26%) patients. The epidemiologic 
investigation revealed that 4/41 (9,73%) patients had 
received blood transfusions before, 15/41 (36,58%) 
patients had surgery (apendicectomy, ovarectomy, 
gastrectomy, diagnosis or therapeutic splenectomy, 
laborious teeth surgery) and 4/41 (9,75%) patients 
associated both epidemiologic conditions for hepatitis viral 
infection. 
Within the analyzed group, the predominant was 
the B-cell lineage – 39/41 (95,12%) patients, and, the T-
cell lineage was found in only 2/41 (4,87%) patients. Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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The patients’ distribution according to the 
histological type of CLD is the following: diffuse large B-
cell non-Hodgkin lymphoma – 13/41 (31,70%) patients, 
small B-cell NH lymphoma – 11/41 (26,82%) patients, 
follicular NH lymphoma – 3/41 (7,31%) patients, 
lymphoblastic lymphoma – 1/41 (2,43%) patients, T-cell 
NH lymphoma - 2/41 (4,87%) patients, Hodgkin’s 
lymphoma – 2/41 (4,87%) patients, chronic lymphocytic 
leukemia – 7/41 (17,07%) patients and Waldenstrom 
disease – 2/41 (4,87%) patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The aggressive form of CLD was found in 19/41 
(46,34%) patients and the indolent type (non-aggressive) 
in 22/41 (63,5%) patients.  
The hepatitis viral infections associated in our 
group were: HBV infection in 14/41 (34,14%) patients, 
HCV infection in 24/41 (58,53%) patients, the double 
association HBV + HDV in 1/41 (2,43%) patients, HBV + 
HCV in 1/41 (2,43%) patients and the triple association 
HBV + HCV+ HDV also in 1/41 (2,43%) patients.  
Phenotype's distribution
B-cell
T-cell
2 patients (4,87%)
39 patients (95,12%)
Fig.1 The B/T phenotype distribution of CLD in the study group 
Hystological type distribution
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02468 1 0 1 2 1 4
1
Waldenstrom macroglobulinemia
CLL
Hodgkin's lymphoma
T-cell NHL
B-cell lymphoblastic NHL
Folicular NHL
Diffuse small B-cell NHL
Diffuse large B-cell NHL
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Fig.2 The distribution according to the histological type of the CLD in the study group Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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Analyzing the correlation between the viral 
infection and the type of CLD (aggressive / indolent), we 
observed that within the group with HBV infected patients 
9/14 (64,28%) have aggressive histological type and 5/14 
(35,71%) patients have the indolent histological type of 
CLD, compared to the group with HCV infected patients in 
which 15/24 (62,5%) have non-aggressive histological 
type and 9/24 (37,5%) patients have an aggressive type 
of CLD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical signs 
 
Clinical signs   
B signs  14/41 (43,34%) 
     * Fever  1/19 (5,26%) 
Patient's distribution according to viral infection
1 patient (2,43%)
1 patient (2,43%)
1 patient (2,43%)
24 patients (58,53%)
14 patients (34,14%)
HBV
HCV
HBV+HDV
HBV+HCV
HBV+HCV+HDV
Fig.3 The distribution of patients according to the viral infection 
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9 patients (37,5%)
15 patients (62,5%)
Fig.4 The correlation between the viral infection and the type of CLD Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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     * Weight loss  4/19 (21,05%) 
     * Sweats  1/19 (5,26%) 
     * All B signs  13/19 (68,42%) 
Superficial/profound adenopathies  29/41 (70,73%) 
Hepatomegaly  38/41 (92,68%) 
Splenomegaly  21/41 (51,21%) 
Extranodal involvement  10/41 (24,39%) 
Jaundice  3/41 (7,31%) 
Bleeding  2/41 (4,87%) 
Peritoneal effusion  1/41 (2,43%) 
Collateral circulation  3/41 (7,31%) 
 
Clinical parameters were monitored. We 
concluded that the B signs were present in 19/41 
(43,34%) patients: fever – 1/19 (5,26%), weight loss – 
4/19 (21,05%), sweats – 1/19 (5,26%) and the association 
of all the three B signs – 13/19 (68,42%). 11/19 (57,89%) 
have an indolent histological type of CLD and 8/19 
(42,10%) an aggressive type of CLD.  
The adenopathies (superficial/profound) were 
present in 29/41 (70,73%) patients; 9/29 (31,03%) 
associate HBV infection, 19/29 (65,51%) – HCV infection 
and 1/29 (3,44%) associate double infection HBV+HCV.  
Hepatomegaly was found in 38/41 (92,68%) 
patients, with equal distribution between the aggressive 
and the indolent CLD – 19/38 (50%) of patients.  
Splenomegaly was present in 21/41 (51,21%) 
patients. 5/21 (23,80%) with HBV infection, 13/21 
(61,90%) patients – with HCV infection and 1/21 (4,76%) 
patients – with HBV+HCV/HBV+HDV/HBV+HDV+HCV 
(one of each). 3/41 (7,31%) patients had splenectomy 
(diagnostic or therapeutic). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The extra-nodal involvement was present in 
10/41 (24,39%) patients; 4/41 (9,75%) patients with HBV 
infection and 6/41 (14,63%) patients with HCV infection. 
The clinical signs of hepatic failure were found in a small 
number of patients, such as: jaundice – 3/41 (7,31%), 
bleedings – 2/41 ( 4,87%), peritoneal effusion – 1/41 
(2,43%), collateral circulation – 3/41 (7,31%).  
The hematological parameters: the median 
hemoglobin was 12 (min 8,5, max 17,4), normal ranges 
being 11-15 g/dl. In our group of patients – 9/41 (21,95%) 
had anemia (Hb < 11 g/dl), 4/9 (44,44%) patients had 
HBV infection and HCV infection, and 1/9 (11,11%) had 
triple viral association (HBV+HVC+HDV). We had 
lymphocytosis in 33/41 (80,48%) patients; 13/33 (39,39%) 
-  aggressive type of CLD: 4/13 (30,76%) patients were 
HBV infected, 8/13 (61,53%) were HCV infected and 1/13 
(7,69%) patients were HBV+HCV infected; 20/33 
(60,60%)- had the indolent type of CLD: 5/20 (25%) 
patients were HBV infected, 13/20 (65%) patients were 
HCV infected, 1/20 (5%) patients were HBV+HDV 
infected and 1/20 (5%) patients were HBV+HCV+HDV 
infected.  
Viral infection-Splenomegaly
1 patient (4,76%)
1 patient (4,76%)
1 patient (4,76%)
5 patients (23,80%)
13 patients (61,9%)
HBV
HCV
HBV+HCV
HBV+HDV
HBV+HCV+HDV
Fig.5  Correlation between viral infection and splenomegaly Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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Thrombocytopenia (ranges under 150.000/mm³) 
was revealed in 13/41(31,70%) patients. In this group, the 
patients had: 7/13 – had an aggressive type of CLD , from 
which 4/7 (57,14%) patients were HBV infected and 3/7 
(42,85%) were HCV infected; 6/13 patients had an 
indolent type of CLD associated in 2/6 (33,33%) patients 
with HBV infection, 2/6 (33,33%) patients had HCV 
infection, 1/6 (16,66%) patients had double HBV+HDV 
infection and 1/6 (16,66%) patients had triple 
HBV+HCV+HDV infection.    
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Fig.6 The correlation between the viral infection, lymphocytosis and aggressive/indolent type of CLD 
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Fig.7 The correlation between the viral infection, thrombocytopenia and aggressive/indolent type of CLD 
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The bone marrow involvement was found in 
23/41 (56,09%) patients. 
The autoimmune features: autoimmune 
hemolytic anemia was present in 3/41 (7,13%) patients, 
all with HCV infection, 2 with indolent histological type of 
CLD and 1 patient with an aggressive type of CLD. The 
cryoglobulinemia was present in 8/41 (19,51%) patients, 
all with HCV infection, with equal distribution between the 
indolent and the aggressive type of CLD.   
 
Biochemical features  
 
Biochemical features   
GOT (U/L)  61 (26-878) 
GPT (U/L)  56 (25-1331) 
AP (U/L)  100 (39-500) 
GGT (U/L)  65 (22-1822) 
TB (mg/dl)  0.9 (0.2-16.8) 
LDH (U/L)  229 (129-1104) 
The data is presented as a 
median value (minimum, 
maximum) 
 
 
High values of GOT (normal ranges 10-40 U/L) 
were revealed in 27/41 (65,85%) patients with: HBV 
infection 6/27 (22,22%), HCV infection 19/27 (70,37%), 
HBV+HDV 1/27 (3,70%) and HBV+ HCV 1/27 (3,70%) 
patients. In our group, GPT was over normal (normal 
ranges 10-37 U/L) found in 32/41 (78,04%) patients, out 
of whom 21/32 (65,62%) had HCV infection, 10/32 
(31,25%) HBV infection and 1/32 (3,12%) patients double 
infection HBV+HCV. Only 8/41 (19,5%) patients had over 
normal serum alkaline phosphatase (normal ranges 40-
150 U/L), out of whom 6/8 (75%) had HCV infection and 
only 2/8 (25%) had HBV infection. Monitoring the GGT 
levels, we observed high values (normal ranges 9-64 U/L) 
in 23/41 (56,09%) patients, most with HCV infection 14/23 
(60,86%). The total bilirubine was high in 12/41 (29,2%) 
patients, most with HCV infection also 4/12 (58,33%) 
patients.  
The serum LDH, an important prognostic and 
activity marker of the hematological disease, was high in 
17/41 (41,46%) patients, out of whom 9/17 patients  have 
an aggressive type of CLD associating the HBV infection 
in 3/9 (33,33%) patients, 5/9 (55,55%) patients had HCV 
infection and one of them associated a double infection 
HBV+HCV 1/9 (11,11%). The other 8 patients with 
elevated serum LDH have an indolent type of CLD:  3/8 
(37.5%) patients with HBV infection and 5/8 (62,5%) 
patients with HCV infection. 
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Fig.8 The correlation between the serum LDH, viral infection and aggressive/indolent type of CLD 
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Therapy 
The patients’ therapy was also monitored. Thus, 
antiviral therapy was received by 12/41 (29,2%) patients: 
Lamivudine 8/41 (19,51%) patients, Ribavirine/Interferon 
4/41 (9,75%) patients. Chemotherapy was administered 
to 32/41 (78,04%) patients: 5/41 (13,19%) had 
monotherapy (alkilant agents) and 27/41 (65,85%) 
patients received combined chemotherapy 
(CVP/CHOP/CHOEP +/- Rituximab, Fludarabine). We 
have to mention that 7/41 (17,07%) patients associated 
Rituximab – 2 patients with HCV infection and 5 with HBV 
infection. Chemotherapy associated to antiviral therapy 
was received by 9/41 (21,95%) patients, most of them 
with HBV infection 6/9 (66,66%). 
Discussions 
Although HBV has a special hepatic tropism, it 
was revealed that there are small quantities of non-
replicative HBV-DNA or viral antigens in mononuclear 
cells from peripheral blood such as monocytes, B-
lymphocytes, CD4 and CD8 T-lymphocytes, leading to the 
idea that the lymphocytes represent an extrahepatic viral 
reservoir. The mechanism through which the viral genom 
persists and replicates within lymphocytes is yet not 
known. HBV could replicate in extrahepatic tissues like 
bone marrow and lymph nodes, being involved in 
extrahepatic pathology. An association of 30% between 
HBV and chronic lymphoproliferative disorders was 
demonstrated and cryoglobulins were found in 15% of the 
patients with HBV infection [5]. 
The reactivation of HBV infection could be the 
result of chemotherapy in patients with CLD associating 
HBV infection, but immunosuppression induced by CLD 
could be an independent risk factor for the reactivation [6]. 
The mechanism of viral reactivation represents the 
activation and increase of viral replication during 
immunosuppressive therapy, revealed by serum increase 
of DNA-HBV, the serum presence of AgHBe, followed by 
immune response mediated by T-lymphocytes, leading to 
an immune mechanism that destroys the infected 
hepatocytes. An analysis of the risk to develop a B-cell 
lymphoproliferative disorder in AgHBs positive patients 
showed that the risk of infection or viral reactivation is 
increased because of the direct immunosuppressive 
effect of the chronic lymphoproliferation and, also, HBV 
could have a part in lymphomagenesis through the 
persistence of small quantities of DNA-HBV in peripheral 
mononuclear cells, leading to a chronic stimulation of B-
cells and clonal transformation in time [6].  
As for the HCV, it was considered that the B-
clone proliferation is happening in bone marrow and liver, 
as a response to chronic stimulation by HCV antigens 
such as E2 protein, this stimulated clone having a high 
risk of malignant transformation. The E2 protein has the 
binding site CD 81, representing the specific hepatocyte 
and B-lymphocyte receptor for HCV. The mechanism 
through which the HCV is leading to a chronic 
lymphoproliferative disorder is thought to be the chronic 
stimulation of B-lymphocytes through immune 
mechanisms [7]. 
Moreover, it was demonstrated that the HCV 
infected patients present the translocation involving the 
oncogene bcl-2 within their peripheral B-lymphocytes, 
representing a high risk of developing a non-Hodgkin 
lymphoma.  
A high prevalence of HCV antibodies and/or 
RNA-HCV in B-cell NHL patients was revealed and it was 
frequently associated with the mixed essential 
cryoglobulinemia. The exact relationship between HCV 
and cryoglobulinemia is not yet known, but it is certain 
that HCV is a chronic stimulus and that cryoglobulins are 
present in 50% of the HCV patients [8]. In HCV infection, 
we find autoimmune phenomena even in the absence of 
cryoglubulinemia and HCV could induce chronic 
lymphoproliferations [9]. The risk factors for 
cryoglobulinemia in HCV infected patients are: female 
sex, alcohol abuse, detectable RNA-HCV in serum, high 
gammaglobulins, high rheumatoid factor [5]. 
The association of HCV infection with T-cell non-
Hodgkin’s lymphomas and Hodgkin’s lymphoma is not 
evident; only 5% of the patients were found with HCV 
infection and Hodgkin’s disease [10]. 
Succesive studies made by Zignego et all in 
1995 [11], 1996 [12] and 1997 analyzed HCV viremia in 
35% patients with B-cell NHL, the most involved 
genotypes being 1b (61% of cases) and 2a (14% of 
cases). HCV was more frequent in low-grade malignity 
lymphomas. Other studies [13, 14, 15] do not reveal a 
higher prevalence of HCV infection in NHL patients, 
suggesting that HCV infection – NHL association is strictly 
related to geographic prevalence of HCV infection. 
Most of the studies showed the relationship 
between HCV and low grade NHL, especially 
immunocytoma, but there is also a strong association with 
marginal lymphoma - Saadoun et al (2005) revealing a 
regression of a splenic lymphoma after antiviral therapy, 
thus suggesting the role of HCV in lymphomagenesis [16]. 
Published results showed the HCV prevalence in non-
gastric MALT lymphomas - Arcaini et al (2007), the most 
prevalent sites being the skin, salivary glands and the 
socket [17]. The HCV role in gastric MALT lymphomas 
was demonstrated in 2002 by the isolation of RNA-HCV in 
gastric mucosa (18). The most frequent extra-nodal sites 
of NHL associated to HCV infection are the liver and 
salivary glands [19, 20, 21, 22].  
Conclusions 
The preliminary results of our study are in 
agreement with the literature data. A high frequency of 
chronic lymphoproliferative disorders associated with Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
  328 
© 2010, Carol Davila University Foundation
hepatitis virus infections was found in women, especially 
over 50 years old. B-cell CLD was the most frequent 
associated with hepatitis viral infection. In our group, the 
HCV infection is the most frequent hepatitis virus infection 
and highly associated with the non-aggressive histological 
type of CLD, the presence of adenopathies, 
hepatomegaly, splenomegaly and extra-nodal 
involvement. The lymphocytosis is significantly correlated 
with the HCV infection; the autoimmune phenomena were 
rare and found only in HCV infected patients. Moreover, 
the liver status was modified more, within the same 
subgroup of patients.  
All clinical, hematological and biochemical 
parameters will be analyzed in dynamics and correlated 
with the administered therapy and the dynamics of the 
disease course.  
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